Competitive Technologies submits FDA application for pain management device

The device has CE certification from the EU allowing European sales for this non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The company has exclusive worldwide rights to this patented device. The device uses a multi-processor designed to create self-like neurons by applying surface electrodes to the skin to simultaneously treat multiple pain areas.

John Nano, chairman, president and CEO of Competitive Technologies, said: “This device targets the American Pain Society’s goal of reducing pain related suffering. The company’s objective is to commercialize this device worldwide. Based upon the European CE approval status, we have signed a letter of agreement with a billion-dollar European healthcare company for exclusive European distribution rights.”